Chlorpromazine-induced neuroleptic malignant syndrome and its response to diazepam.
We have observed two cases of chlorpromazine-induced neuroleptic malignant syndrome (NMS); both were transiently responsive to intravenous diazepam challenge, but not to blind placebo or amyobarbitol. The interrelationship, via feedback between central dopaminergic and gamma-aminobutyric (GABA) systems is reviewed. A theoretical role for a relative DA-GABA imbalance during NMS and treatment implications are discussed.
D001921:Brain / Q000378:metabolism; D002746:Chlorpromazine / Q000009:adverse effects*; D003975:Diazepam / Q000627:therapeutic use*; D004298:Dopamine / Q000378:metabolism; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D004421:Dystonia / Q000139:chemically induced*; D005260:Female; D005334:Fever / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D013577:Syndrome; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
D005680:gamma-Aminobutyric Acid; D003975:Diazepam; D002746:Chlorpromazine; D004298:Dopamine